메뉴 건너뛰기




Volumn 5, Issue , 2008, Pages

Access to high cost medicines in Australia: Ethical perspectives

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; GEFITINIB; IMATINIB; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRASTUZUMAB;

EID: 44949144929     PISSN: 17438462     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-8462-5-4     Document Type: Article
Times cited : (10)

References (33)
  • 1
    • 0032986775 scopus 로고    scopus 로고
    • The Australian National Medicinal Drug Policy
    • 10.1046/j.1440-1762.1999.00291.x
    • Sansom L The Australian National Medicinal Drug Policy J Quality Clinical Practice 1999, 19:31-35. 10.1046/j.1440-1762.1999.00291.x
    • (1999) J Quality Clinical Practice , vol.19 , pp. 31-35
    • Sansom, L.1
  • 3
    • 84861112051 scopus 로고    scopus 로고
    • Justice
    • New York, Oxford University Press Beauchamp TL and Childress JF 5th
    • Beauchamp TL Childress JF Justice Principles of Biomedical Ethics New York, Oxford University Press Beauchamp TL and Childress JF 5th 2001, 225-282
    • (2001) Principles of Biomedical Ethics , pp. 225-282
    • Beauchamp, T.L.1    Childress, J.F.2
  • 6
    • 16544384964 scopus 로고    scopus 로고
    • The subsidy of pharmaceuticals in Australia: Processes and challenges
    • 15527399
    • Sansom L The subsidy of pharmaceuticals in Australia: Processes and challenges Aust Health Rev 2004, 28:194-205. 15527399
    • (2004) Aust Health Rev , vol.28 , pp. 194-205
    • Sansom, L.1
  • 8
    • 0038408597 scopus 로고    scopus 로고
    • Evidence-based medicine as an instrument for rational health policy
    • 10.1023/A:1022947707243 12769414
    • Biller-Andorno N Lie RK ter Meulen R Evidence-based medicine as an instrument for rational health policy Health Care Anal 2002, 10:261-275. 10.1023/A:1022947707243 12769414
    • (2002) Health Care Anal , vol.10 , pp. 261-275
    • Biller-Andorno, N.1    Lie, R.K.2    ter Meulen, R.3
  • 9
    • 0032507379 scopus 로고    scopus 로고
    • Ethics and evidence based medicine
    • Kerridge I Lowe M Henry D Ethics and evidence based medicine BMJ 1998, 316:151-153.
    • (1998) BMJ , vol.316 , pp. 151-153
    • Kerridge, I.1    Lowe, M.2    Henry, D.3
  • 10
    • 2342418618 scopus 로고    scopus 로고
    • Evidence based medicine guidelines: A solution to rationing or politics disguised as science?
    • 1733818 15082812 10.1136/jme.2003.003145
    • Saarni SI Gylling HA Evidence based medicine guidelines: A solution to rationing or politics disguised as science? J Med Ethics 2004, 30:171-175. 1733818 15082812 10.1136/jme.2003.003145
    • (2004) J Med Ethics , vol.30 , pp. 171-175
    • Saarni, S.I.1    Gylling, H.A.2
  • 11
    • 0029384042 scopus 로고
    • Evidence based medicine and ethics
    • 1376770 8558537
    • Hope T Evidence based medicine and ethics J Med Ethics 1995, 21:259-260. 1376770 8558537
    • (1995) J Med Ethics , vol.21 , pp. 259-260
    • Hope, T.1
  • 12
    • 0029165307 scopus 로고
    • Health Policy Approaches to Measuring and Valuing Human Life: Conceptual and Ethical Issues
    • 1615602 7573617
    • Morrow RH Bryant JH Health Policy Approaches to Measuring and Valuing Human Life: Conceptual and Ethical Issues Am J Public Health 1995, 85:1356-1360. 1615602 7573617
    • (1995) Am J Public Health , vol.85 , pp. 1356-1360
    • Morrow, R.H.1    Bryant, J.H.2
  • 13
    • 2342441070 scopus 로고    scopus 로고
    • Ethical issues of cost effectiveness analysis and guideline setting in mental health care
    • 1733826 15082807 10.1136/jme.2003.007047
    • Berghmans R Berg M van den Burg M ter Meulen R Ethical issues of cost effectiveness analysis and guideline setting in mental health care J Med Ethics 2004, 30:146-150. 1733826 15082807 10.1136/jme.2003.007047
    • (2004) J Med Ethics , vol.30 , pp. 146-150
    • Berghmans, R.1    Berg, M.2    van den Burg, M.3    ter Meulen, R.4
  • 14
    • 21644443971 scopus 로고    scopus 로고
    • Tailoring access to high cost, genetically targeted drugs
    • 15963014
    • Hall WD Ward R Liauw WS Brien JE Lu CY Tailoring access to high cost, genetically targeted drugs Med J Aust 2005, 182:607-608. 15963014
    • (2005) Med J Aust , vol.182 , pp. 607-608
    • Hall, W.D.1    Ward, R.2    Liauw, W.S.3    Brien, J.E.4    Lu, C.Y.5
  • 17
    • 85082978480 scopus 로고    scopus 로고
    • Subsidised access to TNFa inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible? [comment]
    • [comment] 15487967
    • Sansom L Subsidised access to TNFa inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible? [comment] Med J Aust 2004, 181:457-458. 15487967
    • (2004) Med J Aust , vol.181 , pp. 457-458
    • Sansom, L.1
  • 18
    • 44949189440 scopus 로고    scopus 로고
    • Lack of evidence for an association between rheumatoid factor status and clinical response in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors
    • Lu CY Williams KM March LM Bertouch J Day RO Lack of evidence for an association between rheumatoid factor status and clinical response in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors Intern Med J 2004, 34:A104.
    • (2004) Intern Med J , vol.34
    • Lu, C.Y.1    Williams, K.M.2    March, L.M.3    Bertouch, J.4    Day, R.O.5
  • 19
    • 7044247960 scopus 로고    scopus 로고
    • Subsidised access to TNFa inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible?
    • 15487967
    • Lu CY Williams KM March LM Bertouch J Day RO Subsidised access to TNFa inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible? Med J Aust 2004, 181:457. 15487967
    • (2004) Med J Aust , vol.181 , pp. 457
    • Lu, C.Y.1    Williams, K.M.2    March, L.M.3    Bertouch, J.4    Day, R.O.5
  • 20
    • 11844262650 scopus 로고    scopus 로고
    • Subsidised access to TNF-alpha inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible?
    • 15651955
    • Mann EL Subsidised access to TNF-alpha inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible? Med J Aust 2005, 182:47-48. 15651955
    • (2005) Med J Aust , vol.182 , pp. 47-48
    • Mann, E.L.1
  • 21
  • 22
    • 0034715904 scopus 로고    scopus 로고
    • Accountability for reasonableness
    • 1119050 11090498 10.1136/bmj.321.7272.1300
    • Daniels N Accountability for reasonableness BMJ 2000, 321:1300-1301. 1119050 11090498 10.1136/bmj.321.7272.1300
    • (2000) BMJ , vol.321 , pp. 1300-1301
    • Daniels, N.1
  • 23
    • 4344629209 scopus 로고    scopus 로고
    • Access to high cost drugs in Australia: Risk sharing scheme may set a new paradigm
    • 514195 15321884 10.1136/bmj.329.7463.415
    • Lu CY Williams KM Day RO March LM Sansom L Bertouch J Access to high cost drugs in Australia: Risk sharing scheme may set a new paradigm BMJ 2004, 329:415-416. 514195 15321884 10.1136/bmj.329.7463.415
    • (2004) BMJ , vol.329 , pp. 415-416
    • Lu, C.Y.1    Williams, K.M.2    Day, R.O.3    March, L.M.4    Sansom, L.5    Bertouch, J.6
  • 24
    • 33845201146 scopus 로고    scopus 로고
    • Recent developments in targeting access to high cost medicines in Australia
    • 10.1186/1743-8462-2-28
    • Lu CY Ritchie J Williams KM Day RO Recent developments in targeting access to high cost medicines in Australia Aus NZ Health Policy 2005, 2:28. 10.1186/1743-8462-2-28
    • (2005) Aus NZ Health Policy , vol.2 , pp. 28
    • Lu, C.Y.1    Ritchie, J.2    Williams, K.M.3    Day, R.O.4
  • 25
    • 39049114515 scopus 로고    scopus 로고
    • The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia
    • 10.1186/1743-8462-4-26
    • Lu CY Ritchie J Williams K Day R The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia Aus NZ Health Policy 2007, 4:26. 10.1186/1743-8462-4-26
    • (2007) Aus NZ Health Policy , vol.4 , pp. 26
    • Lu, C.Y.1    Ritchie, J.2    Williams, K.3    Day, R.4
  • 26
    • 33644621310 scopus 로고    scopus 로고
    • Toward ethical review of health system transformations
    • 1592698 16449582 10.2105/AJPH.2005.065706
    • Daniels N Toward ethical review of health system transformations Am J Public Health 2006, 96:447-451. 1592698 16449582 10.2105/AJPH.2005.065706
    • (2006) Am J Public Health , vol.96 , pp. 447-451
    • Daniels, N.1
  • 27
    • 33644833351 scopus 로고    scopus 로고
    • Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: Are we on target?
    • 10.1111/j.1445-5994.2005.00992.x 16409309
    • Lu CY Williams KM Day RO Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: Are we on target? Intern Med J 2006, 36:19-27. 10.1111/ j.1445-5994.2005.00992.x 16409309
    • (2006) Intern Med J , vol.36 , pp. 19-27
    • Lu, C.Y.1    Williams, K.M.2    Day, R.O.3
  • 28
    • 38549133605 scopus 로고    scopus 로고
    • The funding and use of high-cost medicines in Australia: The example of anti-rheumatic biological medicines
    • 10.1186/1743-8462-4-2
    • Lu CY Williams K Day R The funding and use of high-cost medicines in Australia: The example of anti-rheumatic biological medicines Aus NZ Health Policy 2007, 4:2. 10.1186/1743-8462-4-2
    • (2007) Aus NZ Health Policy , vol.4 , pp. 2
    • Lu, C.Y.1    Williams, K.2    Day, R.3
  • 29
    • 0035459678 scopus 로고    scopus 로고
    • The ethics of pharmaceutical benefit management
    • 10.1377/hlthaff.20.5.150 11558699
    • Burton SL Randel L Titlow K Emanuel EJ The ethics of pharmaceutical benefit management Health Aff (Millwood) 2001, 20:150-163. 10.1377/ hlthaff.20.5.150 11558699
    • (2001) Health Aff (Millwood) , vol.20 , pp. 150-163
    • Burton, S.L.1    Randel, L.2    Titlow, K.3    Emanuel, E.J.4
  • 30
    • 33646244039 scopus 로고    scopus 로고
    • Accessing health outcome data on high cost medicines in Australia
    • 16618242
    • Lu CY Williams KM Day RO Accessing health outcome data on high cost medicines in Australia Med J Aust 2006, 184:411-413. 16618242
    • (2006) Med J Aust , vol.184 , pp. 411-413
    • Lu, C.Y.1    Williams, K.M.2    Day, R.O.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.